8-K: Candel Therapeutics' CAN-2409 Receives FDA Regenerative Medicine Advanced Therapy Designation for Prostate Cancer

Candel Therapeutics announced that its lead immunotherapy candidate, CAN-2409, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for the treatment of newly diagnosed localized prostate cancer, based on positive Phase 3 clinical trial data.

Summary

• Candel Therapeutics, Inc. (Nasdaq: CADL) announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CAN-2409 (aglatimagene besadenovec).
• The RMAT designation is for CAN-2409's use in treating newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease.
• CAN-2409 had previously received FDA Fast Track designation for the same indication.
• The RMAT designation was based on positive data from Candel's Phase 3 randomized, placebo-controlled clinical trial.
• The Phase 3 trial, announced in December 2024, met its primary endpoint, showing a statistically significant improvement in disease-free survival (DFS) (p=0.0155).
• Patients receiving CAN-2409 plus valacyclovir and standard of care (SoC) external beam radiation therapy (n=496) demonstrated a 30% reduction (HR 0.70) in the risk for prostate cancer recurrence or death compared to placebo (n=249).
• Prostate-specific DFS improved with a 38% risk reduction (HR 0.62; p=0.0046) in the CAN-2409 arm.
• A significant increase in patients achieving a prostate-specific antigen (PSA) nadir of <0.2 ng/ml was observed in the CAN-2409 arm (67.1%) versus placebo (58.6%) (p=0.0164).
• Pathological complete response in 2-year post-treatment biopsies was 80.4% in the CAN-2409 arm compared to 63.6% in the control arm (p=0.0015).
• The safety profile of CAN-2409 was consistent with previous studies, with no new safety signals identified.
• The pivotal Phase 3 clinical trial in prostate cancer was conducted under a Special Protocol Assessment (SPA) agreed with the FDA.
• Candel anticipates submitting its Biologics License Application (BLA) for CAN-2409 at the end of 2026.

Sentiment

Score: 9

Explanation: The announcement of FDA RMAT designation, coupled with robust positive Phase 3 clinical trial data for a significant indication like prostate cancer, represents a highly favorable development for Candel Therapeutics. The designation expedites regulatory review, and the strong efficacy and safety profile of CAN-2409 suggest a high potential for market approval and impact.

Positives

• FDA RMAT designation expedites development and review, offering intensive FDA guidance and potential for rolling and priority review for BLA.
• CAN-2409's Phase 3 trial met its primary endpoint, demonstrating statistically significant improvement in disease-free survival (DFS) (p=0.0155).
• The treatment resulted in a 30% reduction (HR 0.70) in the risk of prostate cancer recurrence or death.
• CAN-2409 improved prostate-specific DFS with a 38% risk reduction (HR 0.62; p=0.0046).
• A significant increase in patients achieving a PSA nadir of <0.2 ng/ml (67.1% vs. 58.6%; p=0.0164) indicates improved disease control.
• High pathological complete response rate of 80.4% in 2-year post-treatment biopsies compared to 63.6% in the control arm (p=0.0015).
• Favorable tolerability profile with over 1,000 patients dosed to date, supporting combination with standard of care.
• CAN-2409 also holds FDA Fast Track designation for prostate cancer, PDAC, and NSCLC, and Orphan Drug Designation for PDAC, indicating broad potential and regulatory support.

Risks

• The timing and advancement of current and future development programs may differ from expectations.
• Final data from preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials.
• The company's ability to efficiently discover and develop product candidates is subject to risks.
• The company's ability to obtain and maintain regulatory approval of product candidates is not guaranteed.
• Maintaining intellectual property rights is crucial and subject to risks.
• Implementation of the company's business model, including strategic plans, carries inherent uncertainties.

Future Outlook

Candel Therapeutics anticipates submitting its Biologics License Application (BLA) for CAN-2409 for intermediate-to-high-risk localized prostate cancer at the end of 2026. The company expects the RMAT designation to facilitate the BLA filing process and aims to introduce a new treatment option for early-stage prostate cancer patients, an area with minimal innovation over the past two decades.

Management Comments

• "Receiving the FDA’s RMAT designation underscores the critical unmet need in patients with early, localized prostate cancer and validates the promising clinical activity observed with CAN-2409."
• "This designation further supports the design of our phase 3 study, including the DFS primary endpoint agreed upon with the FDA during the SPA negotiation."
• "We look forward to collaborating with the FDA to pursue an expeditious approval of CAN-2409 once we submit our BLA—currently anticipated at the end of 2026."
• "Our aim is to introduce a new treatment option for patients at the early stages of prostate cancer, a disease that has seen minimal innovation over the past two decades."
• "We expect the RMAT designation to facilitate the BLA filing process and bring us closer to achieve this objective."

Industry Context

The RMAT designation for CAN-2409 positions Candel Therapeutics as a significant player in the oncology biopharmaceutical space, particularly within the prostate cancer treatment landscape. This designation, coupled with strong Phase 3 data, highlights the potential for a novel, multimodal biological immunotherapy to address a critical unmet medical need in a disease area that has seen limited innovation in recent decades. It suggests a potential shift towards advanced regenerative medicine approaches for solid tumors, aligning with broader industry trends focusing on targeted and immune-modulating therapies.

Comparison to Industry Standards

• The 30% reduction in risk for prostate cancer recurrence or death (HR 0.70) and 38% risk reduction in prostate-specific DFS (HR 0.62) for CAN-2409 are strong efficacy signals, potentially outperforming or complementing existing standard-of-care treatments for intermediate-to-high-risk localized prostate cancer, which often include radiation therapy, surgery, or active surveillance.
• The 80.4% pathological complete response rate in 2-year post-treatment biopsies is a notable outcome, suggesting a high level of tumor eradication compared to typical outcomes with radiation alone or other non-surgical interventions.
• The favorable safety profile of CAN-2409, with over 1,000 patients dosed and no new safety signals, is critical for a new therapy, especially when considering combination with existing standard of care, and compares favorably to the known side effect profiles of chemotherapy or more aggressive surgical interventions.
• The RMAT designation itself places CAN-2409 among a select group of therapies recognized by the FDA for their potential to address serious conditions with unmet needs, indicating a high level of confidence from the regulatory body in the preliminary clinical evidence, similar to other breakthrough therapies in oncology.

Stakeholder Impact

• **Shareholders**: Highly positive impact due to significant regulatory milestone (RMAT designation) and strong clinical data, potentially leading to increased investor confidence and share price appreciation.
• **Patients**: Potential for a new, innovative treatment option for newly diagnosed localized prostate cancer patients with intermediate-to-high-risk disease, addressing an unmet medical need and offering improved disease-free survival and pathological complete response.
• **Healthcare Providers**: Introduction of a novel biological immunotherapy that could expand treatment paradigms for prostate cancer, offering a new tool for managing the disease.
• **Competitors**: May face increased competition in the prostate cancer treatment market if CAN-2409 gains approval, potentially prompting accelerated development of their own pipelines or strategic adjustments.

Next Steps

• Collaboration with the FDA to pursue expeditious approval of CAN-2409.
• Submission of Biologics License Application (BLA) for CAN-2409, anticipated at the end of 2026.

Key Dates

Recommendation

Keywords

Candel Therapeutics, CAN-2409, Prostate Cancer, FDA, RMAT Designation, Regenerative Medicine Advanced Therapy, Immunotherapy, Clinical Trial, Phase 3, Disease-Free Survival, Biologics License Application, Oncology, Biopharmaceutical, Cancer Treatment